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Introduction 
Dihydropteridine reductase (DHPR: E.C. 1.6.99.7) 
is an essential enzyme in the hydroxylating system 
of the aromatic amino acids and catalyses the re-
generation of tetrahydrobiopterin (BH4), the na-
tural cofactor of phenylalanine, tyrosine and tryp-
tophan hydroxylases. 
DHPR deficiency has been the first defect des-
..:ribed (1) and represents the second most com-
mon defect among BH4 deficiencies, covering a-
bout one third of all forms (2). 
The cDNA encoding DHPR has been cloned in 
1987 (3,4) and is about 1.2 Kb long. The gene 
:1as been assigned to the short arm of chromosome 
-l-, in the region 15.3. It encodes fc)r a protein of 
244 amino acid, active as a homodimer. 
So far, sixteen mutations have been described: 
~()Urteen mutations are uniformly scattered 
throughout the coding region (5-9); two further 
mutations have been identified in the donor splice 
sites of introns 3 and 4, respectively (8). The ma-
jority of mutations are missense mutations, with 
only two resulting in premature termination of 
the peptide chain. A single insertion of one amino 
acid (5) and a frameshift due to one base deletion, 
which also aftects splicing (9) , have also been des-
cribcd. Most mutations have been found in single 
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chromosomes. Only three of them have been 
identified more than oncc. IVS 4ntl has been 
found in two patients from United States (8, Di-
anzani I et aI., manuscript in preparation). The 
others, G23D and H158Y, have been identified 
in Italian patients (6,7). 
We report here the distribution of the DHPR 
mutations in the Italian population. Moreover, 
since DHPR deficiency is a heterogeneous disease 
at clinical level, we . attempted to evaluate genotype/ 
phenotype correlation in a subset of completely 
characterized patients. 
Materials and Methods 
Patients 
Nine unrelated Italian patients with DHPR de· 
ficiency were included in this study. ~\'loreo\'er, 
we considered a patient from Malta, ",hose clin-
ical status and genotype were reported in previous 
studies (10,6). 
Hyperphenylalaninemia was detected at neo· 
natal mass screening or later and a definite di-
agnosis of DHPR deficiency \\"as obtained lw 
measurement of urinar; pterins and enzyme ac-
tivity on dried blood spot. 
Phenot\pc dc{crminariml 
In the .lttempt to distll1gl1ish the ditkrent pheno-
Ptcridine, \ '01. 7 :--';0. 3 
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types, some clinical and biochemical parameters 
were evaluated, when available: pretreatment blood 
phenylalanine concentration, neurotransmitter meta-
bolites concentrations in cerebrospinal fluid (CSF), 
CSF pterin levels, urinary pterin excretion, response 
to oral BH4 loading test (7.5 or 20 mg/kg body 
weight BH4), response to the combined phenylalan-
ine (100 mg/ kg body weight) and BH4 (20 mg/ 
kg body weight) oral loading (11), DHPR activity 
in erythrocytes and/or in fibroblasts, response to 
treatment (12). 
DNA analysis 
Genomic DNA was extracted from peripheral 
blood leucocytes, using the phenol-chloroform 
method. G23D and H158Y mutations were 
searched for in all patients . PCR amplifications of 
genomic DNA were performed by using ap-
propriate primers. In particular, to detect G23D 
PCR was performed with primers 5'-CCAG-
TTGCGGGCCCGAAAAG-3' and 5' -GCGTGG-
ATCCGCGGCGGCTGCA-3'. The amplified pro-
duct was then incubated at 37°C with the specific 
endonuclease Hinf I. When a G- > A change oc-
curs at codon 23, a Hinf I restriction site is creat-
ed in the 106 bp amplified product, yielding two 
fragments of 68 and 38 bp. To detect H158Y, a 
PCR was performed with primers 5'-AGTGG-
TCACTGAGCCATCT-3' and 5'-ACGGGAAC-
CCCAAGCACTT -3' . The amplified product was 
then incubated at 3TC with the specific en-
donuclease Hph I. When a C- > T change occurs 
at codon 158, a Hph I restriction site is abolished 
in the 166 bp amplified product, yielding a frag-
ment of 166 bp, instead of two fragments of 104 
and 62 bp. 
Results 
Molecular characterization 
The molecular characterization of four patients 
was reported previously (6,7): two patients were 
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homozygous for G23D, one was homozygous for 
H158Y and the last patient was a compound het-
erozygous for G23D and a new identified mu-
tation, YlS0C. This mutation was identified in a 
larger analysis of the DHPR coding sequence 
(Dianzani I. et al, manuscript in preparation). By 
enzyme digestion a further patient was found 
homozygote for G23D and another homozygote 
for H158Y. 
Three remaining patients, who did not carry 
either G23D or H158Y, will be subjected to an 
extensive exon-screening study to identifY the 
causal mutations. Geographic origin of the charac-
terized chromosomes could be ascertained: G23D 
was found in one patient from Sicily, two from 
Apulia, and in one from Malta (in total 7 chro-
mosomes); H158Y was found in two patients 
from Sicily (4 chromosomes in total) . We could 
not establish the Italian origin of the new iden-
tified mutation, Y150C, because paternity in this 
patient has not been confirmed. 
Phenotype classification 
In Table 1 the clinical aspects of each patients 
are correlated to the responsible mutations. Since 
DHPR deficiency is very heterogeneous clinically, 
we evaluated all available clinical and biochemical 
parameters to attempt a phenotype classification. 
A fully definition of phenotype, however, is hamp-
ered by difterences in procedures employed for 
screening and diagnosis, as well as for treatment. 
Moreover, the response to the BH4 oral load and 
to the combined phenylalanine + BH4 oral load 
could not be compared, because of lack stan-
dardization of these tests. 
Thus, patients were classified into three pheno-
types, severe, intermediate, and mild, on the basis 
of the need for complete or partial or none treat-
ment, respectively. Five patients with a severe 
phenotype (needing a complete therapy with neu-
rotrasmitter precursors and BH4) lacked DHPR 
activity either in red blood cells or in fibroblasts 
and harboured mutations G23D and H158Y in 
Table 1. Genotype/phenotype correlation in DHPR deficiency in Italy . 
Mutation 
G23D/G23D (n=3 ) 
H158YjHlS8Y (n=2) 
G23DjYlSOC (n=l ) 
DHPR activity Phenotype (RBC-Fibroblasts) 
Severe 
Severe 
Intermediate 
0%-0% 
0%-0% 
O%-ND 
Functional 
defect 
BH4 oral 
load (mg/kg) 
Binding site for NADH Response only to 20 
Increased susceptibility to proteases Response only to 20 
G23D: Binding site fOr NADHjYlSOC:? Respo nes only to 20 
n=I1umber of patients; ND=Not Determined; RBC=Red Blood Cells 
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homozygosity . 
The single patient with an intermediate pheno-
type (needing BH4 monotherapy only) is a com-
pound heterozygote for G23D and Y150C. 
Discussion 
In this study we attempted to identity the 
molecular basis of DHPR deficiency in Italy. So 
far three mutations have been identified in Italian 
patients: two of them, G23D and H158Y, are as-
sociated to a severe phenotype. G23D affects the 
binding site for NADH, whereas H158Y causes 
disruption of the overall protein structure. Both 
mutations deeply inhibit the enzymatic activity in 
in vitro expression studies (6,13). It is noteworthy 
that the single patient with an intermediate pheno-
type is a compound heterozygote for G23D and 
Y150C. Thus, the milder phenotype showed by 
this patient is probably due to a less severe func-
tional damage induced by the concurrent Y150C 
mutation. Y150C affects a tyrosine considered to 
be involved in the pterin binding site, thus es-
sential for the reduction process (14). Moreover, 
this tyrosine is part of a consensus TyrXXXLys. 
This sequence is highly conserved among the 
class of short chain dehydrogenases, which in-
cludes DHPR (15). 
Two patients homozygous for G 151 Sand 
F212C mutations, previously descrihed by Rial! 
( 16), could be considered to have a mild form, by 
our classification. They did not require treatment 
at all or needed only BH4 treatment. They did 
not show enzymatic activity in red blood cells, 
but had a residual activity in fibroblasts, of 4 
and 10%, respectively. These two mutant en-
zymes have not been expressed in in vitro sys-
tem. G151S mutation involves a conservative 
substitution (Gly to Ser), that might explain the 
mild disease state in this patient. In conclusion, 
two mutations, G23D and H158Y, account to-
gether for 55% of DHPR deficient patients in I-
taly. It is interesting to note that a cluster of 
DHPR deficient patients had been identified in 
Southern Italy and the same distribution had 
been found also for PTPS deficiency (17) . Either 
heterozygote advantage or genetic drift could be 
hypothesized to explain the clustering of BH4 de-
fects in Italy, but neither of these mechanisms has 
been demonstrated so far. 
Our data sugg~st that a small number of mu-
tations accounts for most cases of DHPR de-
ficiency in Italy. Accordingly, clinical phenotype 
results more homogeneous as compared to other 
105 
populations . 
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